- 写本
- 医学
- 医師
- 医療
- 図説
- 手術
- 江戸時代
- 華岡青洲
- 記録
「骨腫瘍」の写真・グラフィックス・映像
- 提供元
- 日付
- 種類
- 向き
- カテゴリ
- 色
- 同義語オン
- 提供元
- 日付
- 24時間以内 0
- 48時間以内 0
- 72時間以内 0
- 7日以内 0
- 30日以内 0
- 1年以内 0
- 期間を指定 23
- 日付指定なし 23
- 種類
- 写真 23
- グラフィックス 0
- 映像 0
- 向き
- 縦 1
- 横 22
- 正方形 0
- カテゴリ
- ニュース
- スポーツ
- エンターテインメント
- 教育向け
- カテゴリ指定なし
- 色
- カラー 23
- モノクロ 0
- 同義語辞書
- 古い順
- 1
- 古い順
-Swollen lower leg, 19th-century JapanSwollen lower leg, 19th-century Japan. Illustration of a large venous swelling of the lower leg, from ‘A Surgical Casebook‘, a 19th-century manuscript of hand-painted pictures commissioned by Japanese surgeon Hanaoka Seishu (1760-1835). Diagnosed at the time as a bone tumour, this could be a disorder of the veins or lymphatic system, such as elephantiasis. Hanaoka pioneered the use of general anaesthesia to remove tumours from cancer patients. His book illustrated the cancers and other conditions that he treated, and the patients that came to him for treatment. The illustrations were by an artist named Tangetsu.、クレジット：Ｓｃｉｅｎｃｅ Ｐｈｏｔｏ Ｌｉｂｒａｒｙ／共同通信イメージズ
商品コード: 2023051210205
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Zamudio, Vizcaya (Basque Country, Spain: A scientist introduces liquid into a test tube at the Zamudio Technology Park laboratory in Bilbao, May 23, 2022, in Zamudio, Biscay, Basque Country, Spain. The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022053105636
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Bilbao, Biscay (Basque Country, Spain: (L-R) Quimatryx president Pedro Esnaola, Oncomatryx founder Manuel Sanz and CEO Laureano Simon point to a poster during the presentation of Oncomatryx‘s first clinical trial at the Zamudio Technology Park in Bilbao, May 23, 2022, in Bilbao, Biscay, Basque Country, Spain. The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022052800068
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Zamudio, Vizcaya (Basque Country, Spain: A scientist in the laboratory at Bilbao‘s Zamudio Technology Park on May 23, 2022, in Zamudio, Biscay, Basque Country, Spain. The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022052800053
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Zamudio, Vizcaya (Basque Country, Spain: A scientist introduces liquid into a test tube at the Zamudio Technology Park laboratory in Bilbao, May 23, 2022, in Zamudio, Biscay, Basque Country, Spain. The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022053105340
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Zamudio, Vizcaya (Basque Country, Spain: A scientist in the laboratory at Bilbao‘s Zamudio Technology Park on May 23, 2022, in Zamudio, Biscay, Basque Country, Spain. The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022052800106
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Zamudio, Vizcaya (Basque Country, Spain: A scientist introduces liquid into a test tube at the Zamudio Technology Park laboratory in Bilbao, May 23, 2022, in Zamudio, Biscay, Basque Country, Spain. The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022052800052
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Zamudio, Vizcaya (Basque Country, Spain: A scientist introduces liquid into a test tube at the Zamudio Technology Park laboratory in Bilbao, May 23, 2022, in Zamudio, Biscay, Basque Country, Spain. The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022052800029
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Zamudio, Vizcaya (Basque Country, Spain: A scientist introduces liquid into a test tube at the Zamudio Technology Park laboratory in Bilbao, May 23, 2022, in Zamudio, Biscay, Basque Country, Spain. The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022052800117
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Zamudio, Vizcaya (Basque Country, Spain: A scientist introduces liquid into a test tube at the Zamudio Technology Park laboratory in Bilbao, May 23, 2022, in Zamudio, Biscay, Basque Country, Spain. The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022052800122
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Bilbao, Biscay (Basque Country, Spain: (L-R) Quimatryx president Pedro Esnaola, Oncomatryx CEO Laureano Simón and founder Manuel Sanz on their arrival at the presentation of Oncomatryx‘s first clinical trial at the Zamudio Technology Park in Bilbao on May 23, 2022, in Bilbao, Biscay, Basque Country (Spain). The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022053105544
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Bilbao, Biscay (Basque Country, Spain: (L-R) Quimatryx President Pedro Esnaola, Oncomatryx CEO Laureano Simón and founder Manuel Sanz, during the presentation of Oncomatryx‘s first clinical trial at the Zamudio Technology Park in Bilbao on May 23, 2022, in Bilbao, Biscay, Basque Country (Spain). The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022053105522
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Bilbao, Biscay (Basque Country, Spain: Oncomatryx founder Laureano Simón speaks during the presentation of Oncomatryx‘s first clinical trial at the Zamudio Technology Park in Bilbao on May 23, 2022, in Bilbao, Biscay, Basque Country (Spain). The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022053105440
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Zamudio, Vizcaya (Basque Country, Spain: A scientist introduces liquid into a test tube at the Zamudio Technology Park laboratory in Bilbao, May 23, 2022, in Zamudio, Biscay, Basque Country, Spain. The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022052800054
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Zamudio, Vizcaya (Basque Country, Spain: A scientist introduces liquid into a test tube at the Zamudio Technology Park laboratory in Bilbao, May 23, 2022, in Zamudio, Biscay, Basque Country, Spain. The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022053105634
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Bilbao, Biscay (Basque Country, Spain: Oncomatryx founder Laureano Simón speaks during the presentation of Oncomatryx‘s first clinical trial at the Zamudio Technology Park in Bilbao on May 23, 2022, in Bilbao, Biscay, Basque Country (Spain). The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022053105579
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Bilbao, Biscay (Basque Country, Spain: (L-R) Quimatryx president Pedro Esnaola, Oncomatryx CEO Laureano Simón and founder Manuel Sanz pose during the presentation ceremony of Oncomatryx‘s first clinical trial at the Zamudio Technology Park in Bilbao on May 23, 2022, in Bilbao, Biscay, Basque Country (Spain). The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022053105610
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Bilbao, Biscay (Basque Country, Spain: (L-R) Quimatryx president Pedro Esnaola, Oncomatryx CEO Laureano Simón and founder Manuel Sanz on their arrival at the presentation of Oncomatryx‘s first clinical trial at the Zamudio Technology Park in Bilbao on May 23, 2022, in Bilbao, Biscay, Basque Country (Spain). The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022053105518
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Zamudio, Vizcaya (Basque Country, Spain: A scientist in the laboratory at Bilbao‘s Zamudio Technology Park on May 23, 2022, in Zamudio, Biscay, Basque Country, Spain. The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022052800033
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Zamudio, Vizcaya (Basque Country, Spain: A scientist introduces liquid into a test tube at the Zamudio Technology Park laboratory in Bilbao, May 23, 2022, in Zamudio, Biscay, Basque Country, Spain. The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022053105632
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Bilbao, Biscay (Basque Country, Spain: (L-R) Quimatryx president Pedro Esnaola, Oncomatryx CEO Laureano Simón and founder Manuel Sanz on their arrival at the presentation of Oncomatryx‘s first clinical trial at the Zamudio Technology Park in Bilbao on May 23, 2022, in Bilbao, Biscay, Basque Country (Spain). The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022053105312
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Zamudio, Vizcaya (Basque Country, Spain: A scientist introduces liquid into a test tube at the Zamudio Technology Park laboratory in Bilbao, May 23, 2022, in Zamudio, Biscay, Basque Country, Spain. The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022052800050
2022年05月23日Presentation of the first clinical trial of Oncomatryx for patients with metastatic tumorsMay 23, 2022, Zamudio, Vizcaya (Basque Country, Spain: A scientist introduces liquid into a test tube at the Zamudio Technology Park laboratory in Bilbao, May 23, 2022, in Zamudio, Biscay, Basque Country, Spain. The Basque biopharmaceutical company Oncomatryx has obtained authorization from the American Medicines Agency and the Spanish Medicines Agency to begin clinical trials in people with metastatic tumors in the United States and Spain. The new drug, the first antibody conjugate developed in Europe, targets the tumor microenvironment. The trials begin after more than 15 years of research...23 MAY 2022;CANCER;TUMORS;METASTASIS;METASTATIC;TRIAL;PATIENTS;BONE;ONCOMATRYX..H.Bilbao / Europa Press..05/23/2022 (Credit Image: © H.Bilbao/Contacto via ZUMA Press)、クレジット：©Ｈ．Ｂｉｌｂａｏ／Ｃｏｎｔａｃｔｏ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｓｐａｉｎ Ｒｉｇｈｔｓ ＯＵＴ
商品コード: 2022052800073
- 1
